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The aim of this study was to search for clinical and laboratorial data in 46,XY patients with ambiguous genitalia (AG) and normal
testosterone (T) synthesis that could help to distinguish partial androgen insensitivity syndrome (PAIS) from 5α-reductase type 2
deﬁciency(5α-RD2)andfromcaseswithoutmoleculardefectsinthe ARandSRD5A2genes.Fifty-eightpatients(51families)were
included. Age at ﬁrst evaluation, weight and height at birth, consanguinity, familial recurrence, severity of AG, penile length, LH,
FSH, T, dihydrotestosterone (DHT), Δ4-androstenedione (Δ4), and T/DHT and T/Δ4 ratios were evaluated. The AR and SRD5A2
genes were sequenced in all cases. There were 9 cases (7 families) of 5α-RD2, 10 cases (5 families) of PAIS, and 39 patients had
normal molecular analysis of SRD5A2 and AR genes. Age at ﬁrst evaluation, birth weight and height, and T/DHT ratio were lower
in the undetermined group, while penile length was higher in this group. Consanguinity was more frequent and severity of AG
was higher in 5α-RD2 patients. Familial recurrence was more frequent in PAIS patients. Birth weight and height, consanguinity,
familial recurrence, severity of AG, penile length, and T/DHT ratio may help the investigation of 46,XY patients with AG and
normal T synthesis.
1.Introduction
The disorders of sex development (DSD) with sex ambiguity
and 46,XY karyotype can be classiﬁed in three main groups:
(1) disorders of gonadal development (ovotesticular DSD
and partial gonadal dysgenesis), (2) disorders of testosterone
synthesis(testosteronebiosynthesisdefectslikesteroidogenic
acute regulatory protein (STAR) deﬁciency, side-chain cleav-
age(CYP11A1)deﬁciency,3β-hydroxysteroiddehydrogenase
type II (HSD3B2) deﬁciency, 17α-hydroxylase/17,20-lyase
(CYP17A1) deﬁciency, 17β-hydroxysteroid dehydrogenase
III (HSD17B3) deﬁciency, P450 oxidoreductase (POR) de-
fect; cytochrome b5 (CYB5) defect, and defects in luteiniz-
ing hormone action (LHCGR defect)), and (3) disorders2 International Journal of Endocrinology
of testosterone action [partial (PAIS) androgen insensitivity
syndromes] or metabolization (5α-reductase type 2 deﬁ-
ciency) [1].
Themaindiagnosisforpatientswithambiguousgenitalia
and 46,XY karyotype (46,XY DSD) with normal testosterone
secretion and normal M¨ ullerian duct regression is PAIS or
5α-reductase type 2 deﬁciency. Before puberty, the phe-
notypes of 46,XY DSD due to androgen insensitivity syn-
dromes or 5α-reductase type 2 deﬁciency are, in general,
indistinguishable,particularlywhenthereisnoparentalcon-
sanguinity (5α-reductase type 2 deﬁciency is an autosomal
recessive disorder) or family history consistent with X-linked
inheritance (androgen insensitivity syndromes) [2–5].
Despite the multiple genetic causes of 46,XY DSD,
around 30–40% of cases remain without diagnosis [6].
Currently, there is a frequent, nongenetic variant of 46,XY
DSD characterized by reduced prenatal growth and lack of
clear evidence for any associated malformation or steroido-
genic defect. Additionally, other studies in undetermined
46,XY DSD report that around 30% of cases are associated
with low birth weight, indicating that adverse events in
early pregnancy are frequent causes of congenital nongenetic
46,XY DSD [7, 8].
For that reason, the aim of this study was to search for
clinical and laboratorial features of 46,XY patients with
ambiguous genitalia and normal testosterone synthesis that
could help to distinguish PAIS from 5α-reductase type 2
deﬁciency and from cases without molecular defects in the
AR and SRD5A2 genes.
2. Methods
In the last 10 years (from January 2001 to December
2010), the Interdisciplinary Group for the Study of Sex
Determination and Diﬀerentiation (GIEDDS) from the
Clinical Hospital of the Faculty of Medical Sciences of State
University of Campinas (UNICAMP), Brazil evaluated 58
patients (51 families) with ambiguous genitalia having a
46,XY karyotype and normal testosterone secretion after
hCG stimulation. This study was performed according to
the Helsinki declaration and was approved by the Ethical
Research Committee of Faculty of Medical Sciences of UNI-
CAMP. Informed consent was obtained from all participants
and from parents of participants under 18 years of age.
All patients included in this study were born at term.
They underwent laparoscopy during genitoplasty, orchi-
dopexy, and/or gonadectomy, and no M¨ ullerian structures
were found.
Data were obtained regarding age at ﬁrst evaluation,
weight and length at birth, history of parental consanguinity,
familyhistoryofambiguousgenitaliaorinfertility,severityof
the ambiguous genitalia (according to Sinnecker et al. classi-
ﬁcation [9] and Ahmed et al. external masculinization score
(EMS) [10]), penile length (in z score according to Gabrich
et al. [11]), levels of LH, FSH, total testosterone (T), dihy-
drotestosterone (DHT), T/DHT ratio, Δ4-androstenedione,
and T/Δ4 ratio. LH, FSH, and Δ4-androstenedione were
evaluated by chemiluminescence immunoassay, T and DHT
by radioimmunoassay. T was evaluated at basal levels in all
patients, and in all prepubertal patients, a stimulation test
was carried out by giving 1,500IU of hCG by intramuscular
injections for three consecutive days on an outpatient basis.
Venoussamplesweretakenbeforethetestandapproximately
24 hours after the third hCG injection and T was considered
normal if above than 1,5ng/mL [11]. In patients with
complete puberty (Tanner 4 or 5), a hCG-stimulation test
was carried out only if T was below 9ng/mL.
Molecular analyses of SRD5A2 and AR genes were per-
formed for all patients. The eight exons of AR gene and the
ﬁve exons of SRD5A2 were ampliﬁed from genomic DNA
using the polymerase chain reaction (PCR) followed by
sequencing the fragments with Big Dye Terminator Cycle
SequencingKitV3.1ReadyReaction(ABIPRISM/PEBiosys-
tems). The sequences were compared with the normal se-
quence of each gene (ENSEMBL: ENSG00000049319 and
ENSG00000169083) using CLC Sequence Viewer v.6.2 (free
software).
According to clinical and molecular data, the cases were
classiﬁed in three groups of diagnosis: (1) 5α-reductase
type 2 deﬁciency, (2) PAIS, and (3) undetermined (without
molecular defects in either AR or SRD5A2 gene).
Data were processed in the SPSS program for Windows,
version 16.0, and descriptive analyses for continuous vari-
ables were made by calculating range, means and standard
deviation. The data were compared among the three groups
using Chi-square test or Fisher’s exact test for categorical
variables and Kruskal-Wallis test for continuous variables.
For all analyses, a signiﬁcance level of P<0.05 was adopted.
3. Results
Data from all 58 patients are shown in Tables 1, 2,a n d
3. Nine patients (7 families) showed homozygous or com-
pound heterozygous mutations in SRD5A2 gene (Table 1),
conﬁrming the diagnosis of 5α-reductase type 2 deﬁciency in
these patients. Only c.278delG mutation (patient 4: Table 1)
was not yet described in the literature. Ten patients (5
families) showed hemizygous mutation in AR gene, conﬁrm-
ing the diagnosis of PAIS (Table 2). The remaining 39 cases
showed normal molecular analysis of SRD5A2 and AR genes
(Table 3).
Table 4 shows the frequency of parental consanguinity,
familial recurrence, and severity of ambiguous genitalia in
the three groups. The frequency of parental consanguinity
was signiﬁcantly higher in patients with 5α-reductase type
2 deﬁciency (χ2
(2) = 19.86, P = 0.00005), whereas familial
recurrence was signiﬁcantly more frequent in the groups of
PAIS (χ2
(2) = 8.14, P = 0.02). The severity of ambiguous
genitalia according toSinnecker et al. [9]classiﬁcation (χ2
(2) =
15.49, P = 0.0004) and according to Ahmed et al. [10]s c o r e
(χ2
(2) = 20.89, P = 0.00003) was signiﬁcantly higher in the
group of 5α-reductase type 2 deﬁciency and PAIS in relation
to undetermined cases. Analyzing only the patients with 5α-
reductase type 2 deﬁciency and PAIS, the Sinnecker et al. [9]
classiﬁcation was signiﬁcantly higher in PAIS (χ2
(2) = 6.41,
P = 0.04), while the Ahmed et al. [10] score did not show
signiﬁcant diﬀerences between these two groups of patientsInternational Journal of Endocrinology 3
Table 1: Data from 9 patients (7 families) of 5α-reductase type 2 deﬁciency.
C a s e A g e1( y r ) B i r t hw e i g h t( g ) B i r t hl e n g t h( c m ) P e n i l e( z ) G e n i t a l 1 Genital2 T (ng/mL) T/DHT Mut1 Mut2
1c 0.06 3220 50 −4.6 4 3.0 2.8 28 p.G183S p.G183S
2c 18.2 2900 48 −4.2 3 2.5 9.0 45 c.418delT c.418delT
3c 14.6 2800 47 −4.1 3 2.0 2.8 28 p.R246W p.R246W
4 5.4 2700 48 −4.1 2 9.0 2.2 73 c.278delG c.278delG
5∗1 3.0 2810 47 −4.0 3 1.0 1.8 60 p.Q126R p.G158R
6∗1 0.05 3500 50 −4.0 3 3.0 2.2 44 p.Q126R p.G158R
7c,r 16.7 2600 47 −4.2 3 2.5 4.9 82 p.G196S p.G196S
8∗2c,r 17.3 2900 49 −3.9 3 5.5 13.6 68 p.Q126R p.Q126R
9∗2c,r 11.0 2600 48 −3.1 3 4.0 1.9 63 p.Q126R p.Q126R
Age1: age at ﬁrst evaluation, T: total testosterone, Mut1: mutation 1, Mut2: mutation 2, +: present, −: absent, ∗: related, c: presence of consanguinity, r:
presence of familial recurrence, Genital1: external genitalia according to Sinnecker et al. [9], Genital2: external genitalia according to Ahmed et al. [10].
Table 2: Data from 10 patients (5 families) of PAIS.
Case Age1 (yr) Birth weight (g) Birth length (cm) Penile (z) Genital1 Genital2 T (ng/mL) T/DHT Mutation
1∗1c 28.8 2900 48 −8.7 4 1.0 10.0 33 p.L830F
2∗1c 18.8 3330 48 −8.4 4 2.0 15.0 50 p.L830F
3∗1c 3.0 2800 47 −6.2 4 2.0 3.2 32 p.L830F
4∗1c 1.6 2650 46 −5.2 4 2.0 1.8 60 p.L830F
5∗1c 0.2 3180 50 −6.2 4 5.5 2.0 67 p.L830F
6∗2 0.8 2630 46 −2.7 2 5.5 1.9 63 p.A596T
7∗2 0.2 2900 46 −7.5 2 2.0 1.7 34 p.A596T
8 1.3 3950 49 −3.1 2 6.0 2.9 72 p.A896V
9 19.2 3400 51 −7.5 3 1.0 9.6 46 p.R855H
10c 6.1 3150 49 −4.1 3 3.0 2.3 57 p.M742V
Age1: age at ﬁrst evaluation, T: total testosterone, +: present, −: absent, ∗: related, c: presence of consanguinity, r: presence of familial recurrence, Genital1:
external genitalia according to Sinnecker et al. [9], Genital2: external genitalia according to Ahmed et al. [10].
(Fisher = 1.00). However, these classiﬁcations showed high
negative correlation (r =− 0.675, P = 0.0001).
Table 5 shows range, mean and standard deviation of age
at ﬁrst evaluation, weight and height at birth, penile length
(in z score), levels of T, Δ4-androstenedione, and T/Δ4a n d
T/DHT ratios in the three groups. The levels of LH and
FSH were not compared because only a few patients were in
pubertal age in each group of diagnosis (5α-reductase type 2
deﬁciency: 4 patients, PAIS: 1 patient, and undetermined: 2
patients).Theageatﬁrstevaluationwassigniﬁcantlylowerin
idiopathic cases (P = 0.02). Weight (P = 0.002) and length
(P = 0.02) at birth and T/DHT ratio (P = 0.0001) were
signiﬁcantly lower in undetermined cases, and penile length
was signiﬁcantly higher in this group (P = 0.0001). The T
(P = 0.07) and Δ4-androstendione (P = 0.12) levels and
T/Δ4r a t i o( P = 0.32) did not diﬀer among the three groups.
All patients showed normal Δ4-androstendione levels for age
and pubertal stage and T/Δ4 ratio above 0.8.
4. Discussion
Clinical and laboratorial investigation must include careful
and precise anatomical and hormonal studies (both basal
and after stimulation) prior to gender assignment in 46,XY
patientswithundermasculinization(46,XYDSD),whichcan
be diﬃcult in most cases [1, 8, 12]. The phenotypes of
46,XY DSD due to 5α-reductase type 2 deﬁciency, PAIS, and
disorders in testosterone synthesis may be indistinguishable
in newborns [1–6, 8, 12]. The diﬀerential diagnosis of PAIS
and 5α-reductase type 2 deﬁciency should be established as
soon as possible because individuals with PAIS are usually
recommended to be raised as females, whereas those with
5α-reductase type 2 deﬁciency as males, when the diagnosis
is made early in childhood [1, 6, 8, 12–14].
A correct and early diagnosis is very important because
as a result of pre- and/or postnatal brain exposure to andro-
gens, almost 70% of individuals with 5α-reductase type 2
deﬁciency and 46,XY karyotype raised as girls develop a
male gender identity and change the gender behavior in
adolescence or early adulthood [2, 4, 15–18] .T h ed e g r e eo f
external genital masculinization at birth does not seem to be
related to gender role changes [18].
At puberty, the diﬀerential diagnosis of PAIS and 5α-
reductase type 2 deﬁciency can be easier due to the presence
of gynecomastia, little genital virilization, and body hair in
patients with PAIS, whereas in patients with 5α-reductase
type 2 deﬁciency, there is genital virilization, although not
always with adequate penile growth, absence of gynecomas-
tia, and absentor hypoplastic prostate[2–5]. Alsoatpuberty,
serum levels of LH and T are abnormally elevated in patients
with PAIS [10]. However, in prepubertal patients with PAIS,
serum concentrations of T and LH are generally normal and4 International Journal of Endocrinology
Table 3: Data from 39 patients without molecular defects in SRD5A2 and AR genes.
Case Age1 Birth weight (g) Birth length (cm) Penile (z) Genital1 Genital2 T (ng/mL) T/DHT
1 0.6 2800 47 −4.0 3 5.5 3.7 18
2r 0.08 2650 46 −2.7 2 6.0 3.5 12
3 0.04 2740 47 −4.0 2 6.0 1.9 95
4 0.4 2410 46 −2.7 2 5.0 1.7 8
5 2.8 2700 48 −1.2 2 10.0 1.7 8
6r 4.1 2800 47 −1.1 2 10.0 2.1 7
7 0.6 1650 41 −3.4 2 6.5 2.1 10
8 0.8 2580 46 −3.0 2 8.0 2.7 13
9 13.8 2900 47 −6.5 3 5.0 1.7 1
10r 20.7 2700 46 −5.6 2 6.0 16.0 5
11 0.8 3000 47 −3.4 3 6.0 1.5 3
12 2.4 2500 49 −3.1 3 1.0 1.9 4
13r 2.3 2010 44 −3.7 2 5.0 1.8 6
14r 0.8 2900 47 −3.0 2 6.0 3.4 11
15 8.1 2800 48 −2.0 2 10.0 1.8 30
16r 0.3 2650 47 −2.7 2 5.5 3.6 18
17 10.2 2110 43 −3.1 2 8.0 1.8 18
18 3.8 1430 39 −4.0 2 5.5 2.0 22
19r 0.5 2500 45 −2.7 2 6.0 1.9 9
20 0.04 2810 46 −2.1 3 6.0 2.4 6
21 0.1 2160 43 −2.7 2 6.0 2.3 8
22 0.2 2600 47 −3.4 2 5.0 3.4 8
23r 0.1 3000 48 −4.2 2 5.0 2.0 10
24r 0.5 2700 48 −2.4 2 9.0 6.6 17
25 0.07 1740 42 −3.1 2 5.0 1.8 9
26c 0.4 1700 41 −2.1 2 9.0 2.7 9
27 1.9 2330 42 −2.9 2 6.0 3.4 17
28 0.02 2900 49 −2.7 2 6.0 1.8 9
29 0.2 1540 40 −4.5 2 6.0 1.7 8
30 0.06 2190 42 −3.4 3 3.0 2.6 5
31 0.7 1430 40 −3.4 2 6.0 1.6 8
32 0.2 2250 43 −2.4 3 5.5 1.6 55
33r 0.3 2990 49 −2.4 2 6.0 1.6 16
34 10.9 2800 47 −6.6 3 1.0 1.7 8
35 2.6 2700 49 −3.1 2 6.0 4.0 13
36 0.1 2800 50 −2.1 2 8.5 1.9 18
37r 3.7 2450 49 −2.7 2 4.0 2.5 12
38c,r 0.02 2900 48 −2.7 3 6.0 2.2 4
39r 2.7 3400 51 −5.9 2 1.0 1.9 12
Age1: age at ﬁrst evaluation, +: present, −: absent, c: presence of consanguinity, r: presence of familial recurrence, T: total testosterone, Genital1:e x t e r n a l
genitalia according to Sinnecker et al. [9], Genital2: external genitalia according to Ahmed et al. [10].
do not help to establish the diagnoses [13]. In addition,
T/DHT is usually elevated in prepubertal patients with 5α-
reductase type 2 deﬁciency [4]. Surprisingly, in this sample,
the T/DHT ratio did not allow diﬀerentiation between
patients with PAIS and 5α-reductase type 2 deﬁciency, but
it was important to diﬀerentiate these two groups from
undetermined cases. Probably, this result was due to the
sensitivity of laboratory methods. Unfortunately, we could
not conﬁrmed these results using more speciﬁc methods like
liquid chromatography linked with tanden mass spectrom-
etry (LC-MS/MS) or immunoassays after organic solvent
extraction [19]. Δ4-androstenedione and T/Δ4r a t i o sw e r e
normal in all patients evaluated. According to George et al.
[20], the diagnosis of 17β-hydroxysteroid dehydrogenase III
deﬁciency in infants younger than 6 months can be excluded
with a basal T/Δ4 ratio above 0.8, with a sensitivity of 100%
andinprepubertalchildrenwiththesamevalueofT/Δ4ratio
after hCG stimulation test, with a sensitivity of 90%.
In the present study, among 51 families evaluated, 7
(13.7%) showed homozygous or compound heterozygous
mutations in SRD5A2 gene, conﬁrming the diagnosis of 5α-
reductase type 2 deﬁciency, 5 (9.8%) showed hemizygousInternational Journal of Endocrinology 5
Table 4: Data from 7 families with 5α-reductase type 2 deﬁciency, 5 families with PAIS, and 39 isolated undetermined cases.
5α-reductase type 2 deﬁciency PAIS Undetermined P value∗
Parental consanguinity +52 2 P = 0.00005
− 23 3 7
Familial recurrence +35 1 3 P = 0.02
− 40 2 6
Ambiguous genitalia Sinnecker et al. [9]
2 13 2 9
P = 0.0004 3 72 1 0
4 15 0
Ambiguous genitalia Ahmed et al. [10] <3.5 67 4 P = 0.00003
≥3.5 33 3 5
∗Chi-square test.
Table 5: Data from 9 patients with 5α-reductase type 2 deﬁciency, 10 patients with PAIS, and 39 isolated undetermined cases.
5α-reductase type 2 deﬁciency PAIS Undetermined P value∗
Age at ﬁrst consultation (yr) 9.6 ± 7.5(0.05–18.2) 8.0 ± 10.0(0.2–28.8) 2.5 ± 4.5(0,02–20,7) P = 0.02
Birth weight (g) 2890 ± 290(2600–3500) 3100 ± 400(2630–3950) 2470 ± 460(1700–3000) P = 0.002
Birth length (cm) 48 ± 1(47–50) 48 ± 2(46–51) 46 ± 3(39–50) P = 0.02
Penile length (z) −4.0 ± 0.4(−4.6–−3.1) −6.0 ± 2.1(−8.7–−2.7) −3.2 ± 1.2(−6.6–−1.1) P = 0.0001
T (ng/mL) 4.6 ± 4.1(1.8–13.6) 4.5 ± 4.4(1.7–15.0) 2.6 ± 1.4(1.5–9.1) P = 0.07
Δ4 (ng/mL) 1.4 ± 0.4(0.8–1.9) 1.1 ± 0.4(0.7–1.9) 1.2 ± 0.3(0.7–1.7) P = 0.12
T/Δ4 ratio 3.0 ± 1.9(1.5–7.2) 3.6 ± 1.9(2.1–7.9) 2.7 ± 0.9(1.8–7.0) P = 0.32
T/DHT ratio 54 ± 19(28–82) 51 ± 15(32–72) 14 ± 16(1–95) P = 0.0001
∗Kruskal-Wallis test.
mutation in AR gene, conﬁrming the diagnosis of PAIS, and
the remaining 39 (76.4%) cases showed normal molecular
analysis of SRD5A2 and AR genes. Based on the literature
available, we expected more cases of PAIS [21, 22]a n du pt o
30–40% of undetermined cases [6, 8]. In addition, probably
more patients would be diagnosed with PAIS and mutations
in the AR gene if the AR promoter region and 3 UTR were
evaluated, and we must also remember that the AR gene
in target tissues from patients with hypospadias is more
methylated than in control children, resulting in a decreased
expression of the AR. This epigenetic alteration of the AR
gene might be involved in the pathogenesis of hypospadias
[23].
As expected, the frequency of parental consanguinity was
higher in patients with 5α-reductase type 2 deﬁciency,
whichisamale-limitedautosomalrecessivedisorder(OMIM
264600), whereas the familial recurrence was higher in PAIS,
an X-linked disorder (OMIM 300068).
Weight and length at birth were lower in undetermined
cases, suggesting that metabolic and endocrine disorders as
fetal malnutrition could play a role in poor external genitalia
development. Morel et al. showed that, in comparison
with PAIS, undetermined 46,XY DSD was characterized
by a high incidence of prematurity and/or intrauterine
growth retardation (30%) [8]. In the present study, 12/39
(30.7%) undetermined cases had birth weight lower than
2,500g. De Andrade Machado Neto et al. [24] showed an
association between prenatal growth retardation and 46,XY
DSD which may be due to genetic factors not clariﬁed yet
or to environmental factors which act early in gestation.
Scaramuzzo et al. recently demonstrated that in the ﬁrst days
of life, small-for-gestational-age male pre-term newborns
have reduced testosterone levels compared with adequate-
for-gestational-age preterm newborns, independently from
the presence of abnormalities of the external genitalia [25].
Low testosterone levels were not observed in our patients
with low birth weight and length probably due to the
gestational age, as all patients included in this study were
born at term. Nutrition is the major intrauterine environ-
mental factor that alters expression of the fetal genome
and may have lifelong consequences (fetal programming).
Alterations in fetal nutrition and endocrine status may result
in developmental adaptations that permanently change the
structure, physiology, and metabolism of the oﬀspring,
predisposing individuals to metabolic, endocrinological, and
cardiovascular diseases in adult life [26, 27]. Furthermore,
it may be that sexual plasticity during development explains
the vulnerability of organisms to androgen inﬂuences, such
as environmental oestrogens or endocrine disruptors [28–
31]. The severity of ambiguous genitalia was higher in 5α-
reductase type 2 deﬁciency in comparison with PAIS and
undetermined cases. The 5α-reductase type 2 deﬁciency
has frequently a classical syndrome of pseudovaginal per-
ineoscrotal hypospadias, characterized by a predominantly
female phenotype at birth and signiﬁcant virilization at
puberty[9].Recentreportshaveshowntheclinicalspectrum
to be heterogeneous, ranging from the classic phenotype to
males with hypospadias and even micropenis [32].6 International Journal of Endocrinology




3 and 4, and Ahmed et al. [10] score below 3.5 than undeter-
mined cases and may be more frequently underdiagnosed.
The penile length, that was higher in undetermined cases,
reinforces this hypothesis.
In conclusion, birth weight and length, parental consan-
guinity, familial recurrence, severity of ambiguous genitalia,
penile length, and T/DHT ratio may help the investigation of
46,XY patients with ambiguous genitalia and normal testos-
terone synthesis.
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